Atlas Venture β Full Portfolio
88 tracked investments Β· listed companies and verified rows first
BiotechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jose Rivera(Executive Officer)Carl Gordon(Director)Jean-Francois Formela(Director)John Leonard(Executive Officer, Director)Rachel Haurwitz(Director)
Board seatJean-François Formela· per SEC Form D
BiotechArlington, US
Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)
Board seatKevin BittermanΒ· per SEC Form D Β· $7M raise Β· filed Aug 2015
RNA-editing therapeutics company using its OPERA technology platform.
BiotechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)Jean-Francois Formela(Director)
Board seatJean-François Formela· per SEC Form D
HealthtechMalvern, US
Mark R. Bausinger(Executive Officer)Stephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)P. Sherrill Neff(Director)Wilfred Jaeger(Director)
Board seatKevin BittermanΒ· per SEC Form D Β· $34.3M raise Β· filed May 2015
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Reza Halse(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $40M raise · filed Jul 2021
Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.
BiotechHealthtechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Peter Dudek(Director)David Grayzel(Director)Nancy Hong(Director)Rachel Humphrey(Director)
Board seatDavid GrayzelΒ· per SEC Form D Β· $95M raise Β· filed Feb 2021
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Lawrence Klein, Ph.D.(Director)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)David Lubner(Director)Edward Hurwitz(Director)Dirk Kersten(Director)
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally.
BiotechHealthtechMedical DevicesNew Brunswick, US
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Ed Mathers(Director)Chau Khuong(Director)Bharatt Chowrira(Executive Officer)Ankit Mahadevia(Director)Michael Sheahan(Executive Officer)Peter Barrett(Director)
Cogent Biosciences discovers, develops, and commercializes therapies targeting genetically defined diseases, with a focus on precision medicine and addressing underlying causes rather than symptoms.
BiotechDigital HealthMedical DevicesCambridge, US
Ben Auspitz(Director)Liam Ratcliffe(Director)Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)
BoardBruce Booth(Director)
Comanche Biopharma is a biopharmaceutical company developing evidence-based therapies for preeclampsia and other life-threatening conditions of pregnancy, with a focus on maternal and neonatal health.
BiotechFemTechHealthtechConcord, US
Arthur Levin(Director)Brendan Bulik-Sullivan(Director)Muzammil Mansuri(Director)Paul Antinori(Executive Officer)Allison August(Executive Officer)Ann Taylor(Director)
Board seatDavid GrayzelΒ· per SEC Form D
Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.
BiotechHealthtechMedfield, US
Jamil Beg(Director of the Issuer)Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Kevin Bitterman(Director of the Issuer)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)
Board seatKevin BittermanKevin BittermanΒ· per SEC Form D
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Matthew Patterson(Director)Kevin Bitterman(Director)Jeff Goater(Director)
Board seatKevin BittermanΒ· per SEC Form D
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)in
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Boston, US
Board seatDavid GrayzelΒ· per SEC Form D Β· $75.8M raise Β· filed Aug 2020
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Carole Faig(Director)Rami Daoud(Executive Officer)Diana Brainard(Director)Rick Modi(Executive Officer, Director)Luc Vandenberghe(Director)Elliott Sigal(Director)
Board seatDavid GrayzelΒ· per SEC Form D
South San Francisco, US
Board seatKevin BittermanΒ· per SEC Form D Β· $45.5M raise Β· filed Dec 2018
BiotechSkillman, US
Thomas Beck(Director)Benjamin Auspitz(Director)Simon Tomlinson(Executive Officer, Director)
Board seatDavid GrayzelΒ· per SEC Form D Β· $22.5M raise Β· filed Jan 2018
HealthtechWaltham, US
Amy Schulman(Director)Tillman Gerngross(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $10M raise · filed Dec 2022
BiotechBoston, US
Andrew Fedder(Executive Officer, Director)Adam Friedman(Executive Officer, Director)Brian Piper(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $136.7M raise · filed May 2025
BiotechSt. Louis, US
Charles Bolten(Director)George H. Capps, II(Executive Officer)Robert Karr(Executive Officer, Director)Michael A. Yeadon(Director)David W. Griggs(Director)Thomas P. Cirrito(Director)
Board seatPeter BarrettRajesh DevrajΒ· per SEC Form D Β· $26M raise Β· filed Aug 2017
BiotechCambridge, US
Michelle Doig(Director)Aaron Royston(Director)Xiaodi Su(Director)Praveen Tipirneni(Executive Officer, Director)
Board seatMichael GladstoneΒ· per SEC Form D Β· $37.5M raise Β· filed Jan 2026
Boston, US
Board seatKevin BittermanΒ· per SEC Form D Β· $135M raise Β· filed Sep 2023
BiotechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)Michael Gladstone(Director)Derek DiRocco(Director)Julie Papanek Grant(Director)John Josey(Director)Natalie Holles(Director)
Board seatMichael GladstoneΒ· per SEC Form D Β· $130M raise Β· filed Feb 2021
HealthtechPortland, US
Edward McNamara(Director)Kevin Bitterman(Director)Yumin Choi(Director)Benjamin Shaw(Executive Officer, Director)Kerry Muse(Director)David Shaw(Director)
Board seatKevin BittermanΒ· per SEC Form D Β· $52.3M raise Β· filed Jul 2015
BiotechSt. Louis, US
Charles Bolten(Director)Rick Ryan(Director)Rajesh Devraj(Executive Officer, Director)John Talley(Director)Robert W. Karr(Executive Officer, Director)Eduardo Martinez(Director)
Board seatRajesh DevrajΒ· per SEC Form D Β· $2.7M raise Β· filed Dec 2016
BiotechCambridge, US
Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)Geoffrey Smith(Director)
BoardMing Fang(Director)Bruce Beutel(Director)
Board seatKevin BittermanΒ· per SEC Form D Β· $60.4M raise Β· filed Jul 2024
BiotechBoston, US
Gary Glick(Executive Officer, Director)Shelley Chu(Director)Jean-Francois Formela(Director)John Leonard(Director)
Board seatJean-François Formela· per SEC Form D · filed Dec 2019
BiotechBoston, US
Jean-Francois Formela(Director)John Leonard(Director)Gary Glick(Executive Officer, Director)Shelley Chu(Director)
Board seatJean-François Formela· per SEC Form D · filed Dec 2019
BiotechBoston, US
Gary Glick(Executive Officer, Director)Jean-Francois Formela(Director)John Leonard(Director)Shelley Chu(Director)
Board seatJean-François Formela· per SEC Form D · filed Dec 2019
BiotechCambridge, US
Gary Glick(Mr. Glick is a director and the President of the Issuer.)Jean-Francois Formela(Director)
Board seatJean-François Formela· per SEC Form D · filed Jun 2016
BiotechBoston, US
Jean-Francois Formela(Director)Vincent Miles(Director)Gary D Glick(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · filed Aug 2018
BiotechBoston, US
Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)
Board seatJean-François Formela· per SEC Form D · $75M raise · filed Jul 2025
BiotechWaltham, US
Barbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)Praveen Tiprirneni(Executive Officer, Director)Timothy Springer(Director)Vikas Goyal(Director)
Board seatKevin BittermanΒ· per SEC Form D Β· $51.5M raise Β· filed Jul 2016
BiotechCambridge, US
Jean-Francois Formela(Director)Rick Lundberg(Executive Officer)Alan Crane(Director)David Madden(Director)Marian Nakada(Director)Brian Gallagher(Director)
Board seatKevin BittermanJean-François Formela· per SEC Form D · $20.2M raise · filed May 2020
BiotechCambridge, US
Brian Gallagher(Director)Jean- Francois Formela(Director)Joshua Resnick(Director)Robert Prentiss(Executive Officer)Daniel Lynch(Director)Ronald C. Renaud, Jr.(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $47.5M raise · filed May 2019
BiotechBerkeley, US
Evan Caplan(Director)Natalie Holles(Director)Charlotte McKee(Director)Thomas Gustafson(Executive Officer)Anna French(Director)Emily Conley(Executive Officer, Director)
Board seatKevin BittermanΒ· per SEC Form D Β· $30M raise Β· filed Jul 2025
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D
Lexington, US
Board seatDavid GrayzelΒ· per SEC Form D Β· $120.1M raise Β· filed Dec 2025
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical Devices
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Waltham, US
Patrick Morley(Executive Officer, Director)Anthony Zingale(Director)Eric Pyenson(Executive Officer)Ronald Nordin(Director)Jeff Fagnan(Director)Paul Maeder(Director)
Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.
Cloud ComputingEnterprise SoftwareNew York, US
DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.
Enterprise SoftwareHardwareSemiconductors
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Jason Rhodes(Director)Anthony Quinn(Director)Gustav Christensen(Director)Donald Nicholson(Director)
Plastiq enables businesses to pay vendors using credit cards while vendors receive payments via wire, ACH, check, or other methods, combined with embedded payment processing and card acceptance solutions for merchant transactions.
FintechSan Francisco, US
Daniel Choi(Executive Officer)Ryan Moore(Director)Jeffrey Bussgang(Director)Kerry Hatch(Director)Eliot Buchanan(Executive Officer, Director)Benjamin Ling(Director)
Recorded Future provides cyberthreat intelligence and AI-powered cyber defense capabilities to help organizations identify and neutralize critical threats.
AI & Machine LearningCybersecurityData & InfrastructureEnterprise SoftwareSomerville, US
Christopher Ahlberg(Executive Officer, Director)Teresa Shea(Director)Staffan Truve(Director)Liautaud Bernard(Director)Rich Miner(Director)Andy Palmer(Director)
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Bruce Booth(Director)Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Stefan Vitorovic(Director)Evan Thackaberry(Executive Officer)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.